Skip to main content
. 2017 May 2;8(29):47675–47690. doi: 10.18632/oncotarget.17544

Figure 1. ATP6v1c1 is frequently amplified in tumors and associated with poor prognosis.

Figure 1

A. ATP6v1c1 is overexpressed or amplified in nearly a third of all breast cancers according to data from the TCGA (n=963) including all breast cancer samples with genomic and gene expression data. B. Survival of patients with ATP6v1c1 gene amplification and/or overexpression is reduced relative to patients with neither ATP6v1c1 overexpression nor amplification. In other analyses from distinct studies, patients were divided by median expression of ATP6v1c1 and their time to relapse C. or metastasis D. was plotted.